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Abstract
Multi-center epidemiological studies must ascertain that their measurements are accurate and reliable. For laboratory
measurements, reliability can be assessed through investigation of reproducibility of measurements in the same individual.
In this paper, we present results from the quality control analysis of the baseline laboratory measurements from the ELSA-Brasil
study. The study enrolled 15,105 civil servants at 6 research centers in 3 regions of Brazil between 2008–2010, with multiple
biochemical analytes being measured at a central laboratory. Quality control was ascertained through standard laboratory
evaluation of intra- and inter-assay variability and test-retest analysis in a subset of randomly chosen participants. An additional
sample of urine or blood was collected from these participants, and these samples were handled in the same manner as the
original ones, locally and at the central laboratory. Reliability was assessed with the intraclass correlation coefficient (ICC),
estimated through a random effects model. Coefficients of variation (CV) and Bland-Altman plots were additionally used to
assess measurement variability. Laboratory intra and inter-assay CVs varied from 0.86% to 7.77%. From test-retest analyses,
the ICCs were high for the majority of the analytes. Notably lower ICCs were observed for serum sodium (ICC=0.50;
95%CI=0.31–0.65) and serum potassium (ICC=0.73; 95%CI=0.60–0.83), due to the small biological range of these analytes.
The CVs ranged from 1 to 14%. The Bland-Altman plots confirmed these results. The quality control analyses showed that the
collection, processing and measurement protocols utilized in the ELSA-Brasil produced reliable biochemical measurements.
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Introduction
The validity of inferences from clinical and epidemio-
logical studies critically depends on the validity and
reliability of measurements in the data collection process.
Quality assurance and quality control measures are
therefore needed throughout the stages of planning and
data collection. For an individual patient in continued care,
the use of quality specifications based on the intraperson
biological variation of an analyte through a certain period
of time is internationally accepted (1). For epidemiological
studies, in which greater laboratory precision facilitates
the detection of associations between variables, quality
can be assessed through the agreement of repeated
measurements from biological samples of a single partici-
pant visit (2).
Investigators in Brazil and in other low and middle
income countries have increasingly been involved in multi-
center studies with centralized laboratory analysis, but
the necessary procedures for quality control have been
infrequently reported. The ELSA-Brasil (Estudo Longi-
tudinal de Saúde do Adulto – Brazilian Longitudinal Study
of Adult Health) study utilized a central laboratory for most
of its analyses, offering an opportunity to describe the
methodology and results of the quality assessment of
these measurements.
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The resource of having a centralized laboratory in the
ELSA-Brasil allowed each research center to have a team
for the collection and processing of the biological material,
which would be stored in cryotubes at –80°C for up to
30 days, and further transported to the central facility. The
negative aspects of this strategy were the need for
centralized training and certification of the teams from
each center, and the increased risk of delay in the return
of results to participants. The most important positive
aspects were the facility for acquisition of the lab kits
and the absence of inter-laboratory variability. The local
processing of the samples decreased the volume of
material transported, resulting in a reduction of costs.
The objective of this report is to present the results of
quality control analyses of baseline laboratory measure-
ments of the ELSA-Brasil.
Material and Methods
Data collection
The ELSA-Brasil study enrolled 15,105 participants in
6 field centers located in 3 different regions of the country
from 2008 to 2010 (3). The study protocol was approved
by ethics committees at each institution, and all partici-
pants gave their written informed consent. Participants
underwent interviews, examinations and collection of
blood and urine specimens, in approximately 6 h at the
local research clinics.
As has been previously described in more detail (4),
blood collection was performed in a fasting state and then,
among those without a diagnosis of diabetes, 2 h after the
ingestion of a 75-g oral glucose solution.
Blood was centrifuged within 30 min of collection, with
aliquots then being separated in an ice bath into cryotubes
previously labeled with bar codes, and stored in freezers
at –80°C until transportation to the central laboratory on
dry ice. Once samples were received, analysis for glucose
(fasting and 2 h), glycated hemoglobin (HbA1c), creati-
nine, sodium, potassium, uric acid, aspartate trans-
aminase (AST), alanine transaminase (ALT), gamma-glutamyl
transferase, total cholesterol, HDL-cholesterol, LDL-
cholesterol, triglycerides, thyroid stimulating hormone (TSH),
insulin (fasting and 2 h) and ultrasensitive C-reactive
protein, as well as serology for Chagas disease were
performed.
Urine was collected over 12 h during the night, prior
to the clinic visit, locally processed and stored for ship-
ment in aliquots as described above. Determinations were
performed centrally for sodium, potassium, calcium,
creatinine and albumin.
Given the large number of participants, multi-center
nature and diversity of measurements, the ELSA-Brasil
required effective and efficient mechanisms of quality
assurance and control for laboratory determinations.
As previously reported (5), the main quality assurance
activities were careful selection of research instruments,
centralized training and certification, pretesting and pilot
studies, and preparation of procedure manuals.
For laboratory measurements, inter-assay CVs were
calculated using the results of internal controls, and intra-
assay CVs using data from several pilot studies on both
fresh and frozen samples.
In addition, we performed test-retest analyses of
specific analytes in 10% of a randomly selected sample
of study participants, with determination of intra- and inter-
assay variability at the central laboratory. In selected
participants, a single additional blood or urine sample
was collected for duplication. Extra blood samples were
collected at the end of the blood drawing process. These
tubes ("blind replicates"), identified only by their bar code
and thus, blind for determination, were handled identically
to the original tubes and sent to the central laboratory at
the same time as the original tubes.
Laboratory results were transmitted to the study’s data
center, where the original and quality control (QC) results
were matched through the bar codes to individual study
participants.
Statistical analysis
Reliability was estimated through the calculation of
intraclass correlation coefficient (ICC) (6), using a random
effects model. A mixed model that also included a fixed
order effect (QC sample minus original sample) was used
for the four analytes for which the fixed effect was statis-
tically significant at the 0.05 level. Confidence intervals
were estimated by the 2.5 and 97.5 percentiles of the
empirical distribution obtained with bootstrap sampling
with 1000 repetitions.
We calculated the CV as the ratio of the standard
deviation of measurement error to the mean of the
analyzed variable.
CV ¼ serror
m
Bland-Altman plots were also produced to graphically
explore the agreement between measurements (7).
Analyses were performed initially on all pairs. To mini-
mize the effect of extreme outliers, we then reanalyzed the
differences after removing pairs presenting a difference
between measurements 43 standard deviations from the
mean or for whom the pair’s mean was 45 standard
deviations from the overall sample mean. Analyses were
performed using SAS software (USA), version 9.3 (8).
Results
The inter- and intra-assay CVs for the analytes are
reported in Table 1. This table also presents external,
analytical CVs (CVa) specifications based on biological
variation, for comparison. CVs obtained were generally
quite small. Intra-assay CVs varied from 0.86% for HbA1C
to 3.97% for urinary calcium; inter-assay CVs varied from
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1.28% for sodium to 7.77% for insulin. Most CVs were
lower than the CVa, with serum creatinine, serum sodium,
and glycated hemoglobin being notable exceptions.
The number of blind replicate QC samples obtained
varied from 72 to 94 across analytes. Fewer QC samples
were available for analytes obtained 2 h after the glucose
load, as participants with diabetes were excluded from this
test.
Table 2 presents QC results for all blind replicate pairs
for each analyte, and Table 3 shows results for pairs after
the removal of outliers. The number of pairs removed
varied from 0 to 4. All analytes had an ICC above 0.93
except for serum sodium (0.50) and potassium (0.73)
(Table 2). The removal of pairs with outliers (Table 3)
generally produced a small improvement in ICCs values,
except for serum sodium, which increased from 0.50 to
0.61.
Figure 1 presents Bland-Altman plots of the pair
differences against average pair values for selected
analytes. Panel A shows data for glycated hemoglobin
and Panel B for fasting insulin, the latter demonstrating a
small systematic difference between initial analyte and the
QC sample (–3.79; 95%CI: –5.83 to –1.76). Other similarly
small differences (Supplementary Figures) were seen
between pairs for serum creatinine (2.34; 95%CI=1.19–
3.49), serum potassium (0.16; 95%CI=0.12–0.20), and
TSH (0.06; 95%CI=0.01–0.11). Although both glycated
hemoglobin and insulin had outliers, their removal had
only a small effect on CV and ICC values.
In order to visualize the pairs and the influence of
outliers, Figure 2 shows results for alanine transaminase,
prior to (Panel A) and after exclusion of outliers (Panel B).
As can be seen in Panel A, a single extreme outlier,
probably due to liver disease, makes QC analysis difficult.
In fact, as can be seen when comparing results for this
analyte in Tables 2 and 3, after outlier exclusions the CV
decreased from 12.5 to 6.33%. The ICCs, prior to and
after this exclusion were high with laboratory variability
accounting for less than 2% of the overall variance.
Figure 3 presents the Bland-Altman plot for serum
sodium, demonstrating the narrow biological range of this
analyte.
Table 1. Intra- and inter-assay coefficients of variation (CV). Baseline exam of the Longitudinal Study of
Adult Health (ELSA-Brasil), 2008–2010.
Inter-assay CV (%)
Intra-assay CV
(%)
Lower control Higher control CV+
(%)
Glucose (mmol/L) 1.24 2.70 2.09 2.80
Glycated hemoglobin (HbA1C - proportion) 0.86 3.01 5.01 1.40
Creatinine - serum (mmol/L) 3.02 6.93 4.52 2.98
Sodium - serum (mmol/L) # 1.44 1.28 0.50
Potassium - serum (mmol/L) # 3.08 2.23 3.50
Aspartate transaminase (TGO/AST) (U/L) 3.17 4.68 2.25 6.15
Alanine transaminase (TGP/ALT) (U/L) 3.17 5.39 2.36 9.70
Gamma-glutamyl transferase (U/L) 2.29 3.81 2.71 6.70
Uric acid (mmol/L) 1.33 2.48 2.53 4.30
Total cholesterol (mmol/L) 1.75 1.76 1.94 2.98
Triglycerides (mmol/L) 1.60 2.02 2.56 9.95
HDL-C (mmol/L) 2.00 2.34 2.25 3.65
LDL-C (mmol/L) # 3.28 2.57 3.90
Calcium - urine (mmol/L) 3.97 4.23 3.75 13.10
Creatinine - urine (mmol/L) 2.06 2.15 2.43 5.50
Sodium - urine (mmol/L) 2.60 1.67 1.71 14.35
Potassium - urine (mmol/L) 2.48 2.62 2.30 12.20
Microalbuminuria (g/L) 1.25 4.86 5.09 17.50
TSH (mIU/L) 3.32 4.65 5.89 9.65
Insulin (pmol/L) 3.64 7.13 7.77 10.55
C-reactive protein (nmol/L) 2.68 4.76 4.31 21.10
+Coefficient of variation based on biological variation components. Ref: SEQC. Comité de Garantia de la
Calidad y Acreditación de Laboratorios. Comisión de Calidad Analítica. 2014. Available at http://www.seqc.
es/es/Comisiones/18/9/102/Base_de_datos_de_Variacion_biologica_%7C_Comision_de_Calidad_Analitica_
%7C_Comite_Cientifico/. #Data not available. HDL-C: high density lipoprotein cholesterol; LDL-C: low
density lipoprotein cholesterol; TSH: thyroid-stimulating hormone.
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Discussion
This study demonstrates the excellent quality of the
sample collection and processing, and laboratory mea-
surement of biochemical analytes of the ELSA-Brasil
study, in a sample of free-living Brazilian adults. Labora-
tory intra- and inter-assay variability was almost always
below recommended international standards. Between-
person variability accounted for more than 90% of the total
variability with few exceptions, and was usually greater
than 98%. For epidemiological studies involving associa-
tions between exposures and diseases, the most inclusive
and relevant of the QC measures is the ICC. The ICC,
also called the reliability coefficient, can be interpreted as
a ratio of the between-individual variance to the total
variance. The existence of noise (underlying within-person
variability) as a percentage of the signal (true value of
exposure, in the case the laboratory values) lowers the
ICC values. Therefore, when testing epidemiological
associations, the greater the noise the more difficult it is
to detect real associations at a level of statistical signifi-
cance. One important, and partially controllable source of
this variability is the intraindividual variation, sometimes
called "measurement error". The overall reliability coeffi-
cient evaluates the fraction of the population variability of a
given variable that are not due to measurement errors
(intra-individual variability). This measurement error could
originate from biological variation or from either pre-
analytical or analytical sources. Here, with samples taken
from a single participant visit, the biological variation was
not evaluated. Pre-analytical errors include those related
to variability in collection (e.g., hemolysis), processing
(e.g., delay in chilling and centrifugation leading to metab-
olism of glucose in the collection tube), storage (e.g.,
inadequate temperature maintenance) and transportation
(e.g., premature thawing). Also to be considered is the
possible mixing of tubes among participants during the
collection processes. In this study, none of the outliers
were clustered to a particular individual participant, indi-
cating that the possibility of serious errors resulting from
switching or erroneously labeling collection tubes or ali-
quots, or assigning laboratory results to the wrong
participant, seem unlikely.
Analytical errors include laboratory determination
errors (e.g., reagent variability between kits). The intra-
and inter-assay CVs available from the ELSA central
Table 2. Quality control analyses of all pairs of analytes. Baseline data of the Longitudinal Study of Adult Health (ELSA-Brasil),
2008-2010.
Description N Mean s2total s
2
error CV (%) ICC 95%CI
Glucose (mmol/L) 93 6.22 2.27 0.0345 3.0 0.99 0.95–1.00
Glycated hemoglobin (HbA1C - proportion) 85 0.053 0.00004 0.000002 2.9 0.94 0.86–0.97
Creatinine - serum (mmol/L) 88 82.2 266 15.6 5.3 0.93 0.89–0.95
Sodium - serum (mmol/L) 88 143 8.68 4.37 1.5 0.50 0.31–0.65
Potassium - serum (mmol/L) 88 4.35 0.13 0.034 4.3 0.73 0.60–0.83
Aspartate transaminase (TGO/AST) (U/L) 88 29.9 2487.3 2.84 5.6 1.00 0.91–1.00
Alanine transaminase (TGP/ALT) (U/L) 88 34.9 5465 18.95 12.5 1.00 0.98–1.00
Gamma-glutamyl transferase (U/L) 88 42.2 2139 2.93 4.1 1.00 1.00–1.00
Uric acid (mmol/L) 88 0.325 0.009 0.00003 1.7 1.00 1.00–1.00
Total cholesterol (mmol/L) 88 5.36 1.21 0.0205 2.7 0.98 0.97–0.99
Triglycerides (mmol/L) 88 1.44 0.502 0.0018 2.9 1.00 0.99–1.00
HDL-C (mmol/L) 88 1.48 0.114 0.0038 4.2 0.97 0.95–0.98
LDL-C (mmol/L) 88 3.21 0.993 0.0087 2.9 0.99 0.98–1.00
Glucose 2 h post 75 g glucose load (mmol/L) 72 7.71 10.7 0.0946 4.0 0.99 0.97–1.00
Calcium - urine (mmol/L) 79 2.65 4.28 0.0081 3.4 1.00 1.00–1.00
Creatinine - urine (mmol/L) 80 9.02 28.6 0.0456 2.4 1.00 1.00–1.00
Sodium - urine (mmol/L) 80 108 2460 2.16 1.4 1.00 1.00–1.00
Potassium - urine (mmol/L) 80 34.3 406 0.62 2.3 1.00 1.00–1.00
Microalbuminuria (g/L) 94 0.01 0.0005 0.000001 10.6 1.00 0.98–1.00
TSH (mIU/L) 75 1.98 5.1 0.026 8.1 1.00 0.99–1.00
Insulin (pmol/L) 75 52.4 1220 47.3 13.1 0.96 0.94–0.98
Insulin - 2 h post 75 g glucose load (pmol/L) 74 397 96500 3190 14.2 0.97 0.91–0.99
C-reactive protein (nmol/dL) 83 26.8 1680 3.27 6.8 1.00 1.00–1.00
N: number of observed pairs; s2total: total variance; s
2
error: error variance; CV: coefficient of variation; ICC: intraclass correlation
coefficient; 95%CI: 95% confidence interval; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol;
TSH: thyroid-stimulating hormone.
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Table 3. Quality control analyses of analytes after removal of outliers. Baseline data of the Longitudinal Study of Adult Health
(ELSA-Brasil), 2008-2010.
Description N Mean s2total s
2
error CV(%) ICC 95%CI
Glucose (mmol/L) 91 6.22 2.29 0.0123 1.78 1.00 0.98–1.00
Glycated hemoglobin (HbA1C - proportion) 81 0.053 0.00004 0.000001 2.05 0.97 0.93–0.99
Creatinine - serum (mmol/L) 87 82.2 250 15.6 5.09 0.93 0.90–0.96
Sodium - serum (mmol/L) 86 143 8.2 3.2 1.25 0.61 0.51–0.70
Potassium - serum (mmol/L) 87 4.34 0.13 0.031 4.06 0.75 0.62–0.84
Aspartate transaminase (TGO/AST) (U/L) 87 29.9 96.3 2.86 5.66 0.97 0.90–0.99
Alanine transaminase (TGP/ALT) (U/L) 86 27.5 169 3.03 6.33 0.98 0.97–0.99
Gamma-glutamyl transferase (U/L) 87 41.1 2133 2.59 3.92 1.00 1.00–1.00
Uric acid (mmol/L) 87 0.325 0.009 0.00003 1.60 1.00 1.00–1.00
Total cholesterol (mmol/L) 88 5.36 1.21 0.0205 2.68 0.98 0.97–0.99
Triglycerides (mmol/L) 86 1.41 0.491 0.0013 2.57 1.00 1.00–1.00
HDL-C (mmol/L) 87 1.47 0.115 0.0033 3.92 0.97 0.96–0.98
LDL-C (mmol/L) 87 3.21 0.712 0.0088 2.91 0.99 0.98–0.99
Glucose 2 h post 75 g glucose load (mmol/L) 70 7.71 7.04 0.0444 2.73 0.99 0.99–1.00
Calcium - urine (mmol/L) 78 2.63 4.28 0.0075 3.27 1.00 1.00–1.00
Creatinine - urine (mmol/L) 79 8.84 28.9 0.0392 2.23 1.00 1.00–1.00
Sodium - urine (mmol/L) 78 106 2510 1.38 1.10 1.00 1.00–1.00
Potassium - urine (mmol/L) 78 32.6 396 0.38 1.89 1.00 1.00–1.00
Microalbuminuria (g/L) 90 0.0067 0.00008 0.0000002 7.29 1.00 0.99–1.00
TSH (mIU/L) 74 1.7 1.26 0.01 7.13 0.99 0.98–0.99
Insulin (pmol/L) 74 52.3 1230 40.5 12.2 0.97 0.95–0.98
Insulin - 2 h post 75 g glucose load (pmol/L) 71 365 61000 1090 9.04 0.98 0.96–0.99
C-reactive protein (nmol/dL) 81 20 489 1.81 5.88 1.00 1.00–1.00
N: number of observed pairs; s2total: total variance; s
2
error: error variance; CV: coefficient of variation; ICC: intraclass correlation coeffi-
cient; 95%CI: 95% confidence interval; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; TSH:
thyroid-stimulating hormone.
Figure 1. Bland Altman plots for glycated hemoglobin. Proportion of total hemoglobin (all pairs, Panel A) and insulin in pmol/L (all pairs, Panel B).
The red line indicates the mean within-pair difference found between the original and the quality control (QC) measures. The green dashed lines
indicate 2 standard deviations above and below the mean, and the blue dotted line the 95%CI for the mean of the within-pair difference.
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laboratory indicate very small error in this part of the
measurement process, in general. With few exceptions,
VCs of measured analytes were lower than the analytical
quality specifications based on components of biological
variation (9). Of note, some analytes, such as insulin, are
typically measured with greater variability.
Thus, the bulk of the variability in reported measure-
ments seems likely to be originated from a combination
of smaller problems in analyte collection, processing and
transportation, coupled with the specific analyte suscepti-
bility to each of these problems.
The markedly lower ICCs of the analytes serum
sodium and potassium highlight an interesting phenom-
enon. As the CVs for these analytes were quite high, the
low ICCs can be attributed to their low between-person
variability, as illustrated by the narrow distribution of the
values in the Bland-Altman plots for serum sodium
(Figure 3) and potassium (Supplementary Figures). The
ranges of these analytes, vital to body function, are tightly
controlled within narrow limits. Despite this, their ICCs
indicated that their relatively high measurement error
would make it more difficult to find statistically significant
associations involving either of them in the ELSA sample.
The CV, popular in reports of measurement error, is of
utility in determining the extent to which the analyte value
of a given participant will vary, in relation to the analyte’s
mean value, from one measurement to the next – a
relevant issue in the determination of the analyte’s clinical
utility. However, as CV evaluation doesn’t take other
variabilities into consideration, it has a lesser role in
evaluating the quality of measurements in epidemiologic
studies of associations. In this study, the blind replicate
CVs were higher than the intra- and inter-assay CVs,
which was caused by the inclusion of not only laboratory
Figure 2. Bland Altman plots for alanine transaminase in U/L (all pairs, Panel A; after exclusion of outliers, Panel B). The red line
indicates the mean within pair difference found between the original and the quality control (QC) measures. The green dashed lines
indicate 2 standard deviations above and below this mean, and the blue dotted line the 95%CI for the mean of the within pair difference.
Figure 3. Bland Altman plot of serum sodium in mmol/L (all pairs),
an example of an analyte with a narrow biological range. The red line
indicates the mean within pair difference found between the original
and the quality control (QC) measures, the green dashed lines
indicate 2 standard deviations above and below this mean, and the
blue dotted line the 95%CI for the mean of the within pair difference.
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measurement variability, but also pre-analytical sources of
error usually present in multi-center studies with central-
ized measurements.
The Bland-Altman plots provide a visual analysis of
these QC results. One can see potentially systematic
differences among replicates, such as that found for
fasting insulin (Figure 2). This difference, when present,
was always small, and most likely due either to the fact
that the QC sample was always drawn last, or to chance,
given the multiple comparisons performed. The plots show
no evidence of increased or decreased variability as a
function of the analyte average value, which might be
present, for example, if inadvertent thawing had led to loss
of analytes. The +/– 2 standard deviations boundaries
were relatively close to the means, once again indicating a
small measurement error.
The decision to report results with and without outliers
is not always easy. For example, it seems logical to use
the ICC and CV obtained for alanine transaminase after
exclusion of the outlier seen in the Bland-Altman plot,
given that the mean of the outlier pair was more than
30 times the mean of the remaining pairs, leading to a
potentially large weighting of this single value. The outlier
value was apparently obtained from a participant with liver
disease and, given the large difference within the pair
(450 U/L), likely outside the range of precision of the
measurement technique. For precision evaluation in an
epidemiological study in which the overwhelming majority
of participants have values within or near the normal
range, inclusion of such outliers makes interpretation of
the findings difficult. As can be seen when comparing
the Bland-Altman plots before and after the outlier exclu-
sion, it obscures the analysis of measurement error of
values within the relevant range. In contrast, outliers in
other analytes, both for average values and those for
differences between the QC sample and its pair, were
close to the exclusion boundaries. As such, these values
should probably be considered measurements within
the relevant range of study, and their differences should
be included in our final estimates of measurement
variability.
Two limitations of our analysis merit mention. First, as
QC samples were collected, processed, and shipped
simultaneously with their corresponding pair samples,
some of the measurement variability occurring during
these steps could have been underestimated. Additionally,
an important aspect of variability – temporal biological
variability – was not assessed, as participants were not
recalled to repeat measurements on another day. Thus,
for a thorough evaluation of the measurement reliability
for epidemiological studies, consideration of this within-
participant day-to-day variability would require incorpo-
ration of data from other studies.
In conclusion, these analyses of measurement vari-
ability are important for QC documentation in multi-center
studies during which strict QC measures are necessary to
guarantee accurate results. The biochemical analytes
of the ELSA-Brasil here reported were measured with
high reliability. Based on this, they should serve well as
exposure variables and co-variables for most studies of
associations, especially given the large sample size of the
cohort.
Supplementary material
Click here to view [pdf].
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